Women Benefit from Immunotherapy as Much as Men

JAMA Oncology reported a systematic review and meta-analysis by Wallis and colleagues, finding for advanced tumors, immune checkpoint inhibitor treatment provided no difference in overall survival benefit between men and women. An earlier study suggested men benefited more, but methodological problems in previous analyses prompted this larger investigation.
This meta-analysis included, through late 2018, studies in advanced solid (organ) cancer evaluating immunotherapy in 23 randomized clinical trials . All trials had overall survival data stratified by sex. Trials comparing immunotherapy regimens were excluded.
- What Is a Meta-Analysis? Meta-analyses are the broadest studies, combining results from multiple independent studies on a subject and statistically analyzing the findings. Their results constitute the strongest scientific evidence.
Comparing Immunotherapy’s Survival Benefits
The 23 studies in the meta-analysis included 9322 men (% 67,9) and 4399 women (% 32,1), mostly in their 70s. Compared with standard treatments, immunotherapy reduced death risk by %25 in men and %23 in women; these values were not statistically different.
Subgroup analyses also found no significant sex difference according to organ of origin, line of treatment, immunotherapy class, methodology, or proportion of women in the study group.
In conclusion , these analyses showed no statistically significant association between immunotherapy effectiveness in advanced cancer and patient sex: women benefit from immune checkpoint inhibitor immunotherapies as much as men.
Sources
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
A Systematic Review and Meta-analysis.
JAMA Oncology, 3 January 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.